Guillain-Barré Syndrome — Research Summary
Printed from RareWays (rareways.com.au) on 27 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Emerging threat of Oropouche virus: Clinical features, experimental models, and virulence.
Alkan Cigdem et al. — Virulence (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42035480/
- 2.
A narrative review of considerations when assessing potential relationships between Guillain-Barré syndrome and vaccines.
Williams Sarah Elizabeth et al. — Human vaccines & immunotherapeutics (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41797542/
- 3.
Envelope protein residue E152 confers enhanced GAS6-dependent cell entry to the African Zika virus strain MR766.
Kamiyama Naganori et al. — Antiviral research (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42263867/
- 4.
Plasma Exchange as a Bridge to Recovery in Severe Pediatric Neurological Diseases in Pediatric Intensive Care.
Şık Güntülü et al. — Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42003220/
- 5.
Proteomic analysis reveals divergent inflammatory mechanisms of COVID-associated Guillain-Barré syndrome.
Ulutekin Can et al. — Journal of molecular medicine (Berlin, Germany) (4 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42399536/
Clinical Trials — Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Completed — Phase 3 — CSL Behring
https://clinicaltrials.gov/study/NCT02027701
- 2.
International Guillain-Barré Syndrome Outcome Study
Completed — Erasmus Medical Center
https://clinicaltrials.gov/study/NCT01582763
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Guillain-Barré Syndrome
Guillain-Barré Syndrome is a rare neurological disorder in which the immune system mistakenly attacks the peripheral nervous system, causing rapidly progressing muscle weakness that can lead to paralysis. It affects approximately 300 Australians each year. Most people recover fully, though recovery can take months and some have lasting effects.
Most Recent Research
Oropouche fever, caused by Oropouche virus (OROV) and transmitted primarily by Culicoides midges, has historically been considered a neglected tropical disease characterized by an acute, self-limiting febrile illness and occasional meningoencephalitis, mostly within or along the Amazon rainforest. However, the explosive 2023-2025 outbreak expanded well beyond the Amazon region, including into the Caribbean, and was associated with a broader clinical spectrum encompassing meningoencephalitis, Guillain - Barré syndrome, persistent viral infection, lethal hemorrhagic fever, fetal loss, and neonatal abnormalities. Experimental animal models of OROV infection are available; however, substantial variation in host susceptibility across species complicates the interpretation of pathogenic mechanisms. The major virulence factor, the NSs protein, mediates inhibition of host cellular transcription, whereas the biological functions of the NSm protein remain largely unknown. This review outlines current knowledge on OROV outbreaks, clinical features, animal models, and virulence determinants, underscoring major knowledge gaps in understanding OROV virulence and pathogenesis.
Common Questions
What is Guillain-Barré Syndrome?
Guillain-Barré Syndrome is a rare neurological disorder in which the immune system mistakenly attacks the peripheral nervous system, causing rapidly progressing muscle weakness that can lead to paralysis. It affects approximately 300 Australians each year. Most people recover fully, though recovery can take months and some have lasting effects.
How many clinical trials are available for Guillain-Barré Syndrome?
RareWays currently indexes 51 clinical trials for Guillain-Barré Syndrome, of which 13 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Guillain-Barré Syndrome come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Guillain-Barré Syndrome.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.